Previous 10 | Next 10 |
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 23 rd Annua...
Vericel (VCEL) has announced that UnitedHealthcare has expanded its medical policy for MACI® to include coverage for patients with symptomatic full-thickness cartilage defects.UnitedHealthcare treats more patients with MACI than any other plan in the U.S. and the revised policy is e...
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHealthcare has expanded its medical policy for MACI ® (autologous cultured chondroc...
Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company’s tissue repair and restoration products are proprietary and backed by medical research showing greater effectiveness than tradition...
MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a speculative position ahead of a potential NexoBrid approval. Now, I am looking to ...
CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 39 th Annua...
Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet. Vericel's growth in 2020 was disrupted by COVID due to restrictions on elective surgeries but rapid growt...
Image source: The Motley Fool. Vericel (NASDAQ: VCEL) Q3 2020 Earnings Call Nov 05, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Vericel (VCEL) Q3 2020 Earnings Call Transcript
Vericel Corporation (VCEL) Q3 2020 Earnings Conference Call November 05, 2020 08:30 AM ET Company Participants Nick Colangelo - President and Chief Executive Officer Conference Call Participants Ryan Zimmerman - BTIG Danielle Antalffy - SVB Leerink Kevin DeGeeter - Oppenheimer Jeffrey Cohen -...
Vericel (VCEL): Q3 GAAP EPS of $0.08 beats by $0.10.Revenue of $32.26M (+5.8% Y/Y) beats by $1.28M.Press Release For further details see: Vericel EPS beats by $0.10, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...